ERBB2 and breast carcinoma: Yoshida et al[16] found that 33 (33%) of 99 patients with HER2-positive breast cancer without pCR turned negative, among whom trastuzumab neoadjuvant treatment had the highest negative conversion rate of 70% (23/33).